Authors
Khabchabov R.G., Makhmudova E.R., Abdullaev A.A., Gafurova R.M., Islamova U.A., Dzhanbulatov M.A., Anatova A.A.
Dagestan State Medical University, Makhachkala
Abstract
Objective. To identify differences between the cardiovascular – renal – metabolic syndrome and separately cardiorenal syndrome on the course of coronary heart disease.
Methods. The study included 111 patients – 71 (59.5%) men and 40 (40.5%) women who were treated at the RCH Hospital No. 2 from 2022 to 2023. The patients were divided into two groups, group 1 included n = 52 with cardiovascular – renal – metabolic syndrome, group 2 included n = 59 with cardiorenal syndrome. The duration of the study is 18 months. Statistical processing of the obtained data was carried out using Excel and Statistica 7.0 programs.
Results. Thus, the primary indicators of LDL cholesterol in the 1st group were 2.9±3.6, in the 2nd group 2.2±3.7 (p = 0.08), and upon re – examination, the ratio of values was as follows – 3 .2±2.8 to 32.7±3.9 (p = 0.06). There was an increase in total cholesterol and triglycerides, and indicators of good HDL cholesterol remained virtually unchanged p<0.05. Patients with stage 2 diabetes mellitus increased by the end of the examination in both groups, but so significantly in relation to the total weight of 2.7% to 1.8%, p = 0.01. During the repeated examination, the indicators of arterial hypertension of the 2nd degree prevailed in the group with cardiovascular – renal – metabolic syndrome 34.6 to 23.7 p = 0.01. But, both upon admission and during re – examination, the increase in arterial hypertension of the 3rd degree exceeded in patients with cardiorenal syndrome 25.0 to 27.1 p = 0.04. The development of acute myocardial infarction predominated in the group with cardiovascular – renal – metabolic syndrome, and the number of repeated events of coronary heart disease, the ratio was 33.6 to 23.4 p = 0.05.
Conclusion. Our study showed that patients with cardiovascular – renal – metabolic syndrome are hospitalized faster and have recurrent development of coronary heart disease. As for deaths, they were equal in patients with cardiovascular – renal – metabolic and cardiorenal syndrome.
Keywords: cardiovascular – renal – metabolic syndrome, coronary heart disease, cardiorenal syndrome, type 2 diabetes mellitus.
References
1. Kuschnir MCC, Bloch KV, Szklo M, et al. ERICA: prevalence of metabolic syndrome in Brazilian adolescents. Journal of Revista de saúde Pública. 2016; 50(11): 256-268.
2. Xiang Y, Zhou W, Duan X, et al. Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case-Control Study in Chinese Women. Circulation. AHA/ASA Journals. 2020; 10(16): 905-927.
3. Ivanova N, Liu Q, Agca C, et al. White matter inflammation and cognitive function in a co-morbid metabolic syndrome and prodromal Alzheimer’s disease rat model. Journal of Neuroinflammation. 2020; 17(1): 29-53.
4. Grgurevic I, Podrug K, Mikolasevic I, et al. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Canadian Journal of Gastroenterology and Hepatology. 2020; 20(1): 14-30.
5. Takashi K, Hiroshi M, Hirotaka W, Daisuke Y, Koichi N, et al. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. Journal Diabetes, Obesity and Metabolism. 2022; 24(6): 2283-2296.
6. Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. AHA/ASA Journals. 2023; 1(48): 1636-1664.
7. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. AHA/ASA Journals. 2019; 13(9): 840-878.
8. Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, adipose tissue and vascular dysfunction. Circulation Research. AHA/ASA Journals. 2021; 12(8): 951-968.
9. Khayyat-Kholghi M, Oparil S, Davis BR, Tereshchenko LG. Worsening kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study. Contribution to journal. 2021; 9(11): 100-111.
10. Hicks CW, Yang C, Ndumele CE, et al. Associations of obesity with incident hospitalization related to peripheral artery disease and critical limb ischemia in the ARIC study. Journal of the American Heart Association. 2018; 7(5): 86-104.
11. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. AHA/ASA Journals. 2021; 14(3): 984-1010.
12. Lee M-K, Han K, Kim MK, et al. Changes in metabolic syndrome and its components and the risk of type 2 diabetes: a nationwide cohort study. Nature Journal Scientific reports. 2020; 10(1): 23-43.
13. Efremova OA, Kamyshnikova LA. Nikitin EA. Parallels of lipid metabolism and hyperhomocysteinemia in patients with ischemic heart disease and metabolic syndrome. Network scientific and practical journal. Scientific result. Series “Medicine and Pharmacy”. 2014; 1(1): 12-19. (In Russ.)
14. Kytikova OYu, Antonyuk MV, Gvozdenko TA, Novgorodtseva TP. Metabolic aspects of the relationship between asthma and obesity. Obesity and metabolism. 2019; 15(4): 9-14. (In Russ.)
